Evidence map›Paper›PMID 28421431›Full record

ArticleDoklady. Biochemistry and biophysics2017

Detection of autoantibodies to potentially amyloidogenic protein, gamma-synuclein, in the serum of patients with amyotrophic lateral sclerosis and cerebral circulatory disorders.

A Yu Roman, E A Kovrazhkina, O D Razinskaya, M S Kukharsky, A V Maltsev, R K Ovchinnikov, O A Lytkina, A P Smirnov, A A Moskovtsev, Yu V Borodina and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. The presence and clinical significance of autoantibodies in amyotrophic lateral sclerosis: a narrative review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

A Yu RomanInstitute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Moscow oblast, 142432, Russia.
E A KovrazhkinaPirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation, Moscow, 117997, Russia.
O D RazinskayaPirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation, Moscow, 117997, Russia.
M S KukharskyInstitute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Moscow oblast, 142432, Russia.
A V MaltsevInstitute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Moscow oblast, 142432, Russia. maltsevandro@mail.ru.
R K OvchinnikovInstitute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Moscow oblast, 142432, Russia.
O A LytkinaInstitute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Moscow oblast, 142432, Russia.
A P SmirnovPirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation, Moscow, 117997, Russia.
A A MoskovtsevResearch Institute of General Pathology and Pathophysiology, Moscow, 125315, Russia.
Yu V BorodinaResearch Center Hospital, Russian Academy of Sciences, Chernogolovka, Moscow oblast, Russia.
A P SurguchovUniversity of Kansas Medical Center, Kansas, USA.
A A UstyugovInstitute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Moscow oblast, 142432, Russia.
N N NinkinaInstitute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Moscow oblast, 142432, Russia.
V I SkvortsovaPirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation, Moscow, 117997, Russia.
Institute of Physiologically Active Compounds · RUMinistry of Health of the Russian Federation · RUInserm · FRResearch Institute of General Pathology and Pathophysiology, the Russian Academy of Medical Sciences · RURussian Academy of Sciences · RUUniversity of Kansas Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we analyzed serum for the presence of antibodies to gamma-synuclein in patients with amyotrophic lateral sclerosis (ALS) compared to the control group of patients with other neurological diseases and healthy control donors. As a result, antibodies against gamma-synuclein are not an ALS-specific feature and have been identified in patients with ALS as well as in the control group patients. Patients with the impaired cerebral circulation showed increased incidence of autoantibodies to gamma-synuclein, yet the difference lacks statistical representativeness due to limited sample size.

Indexed as

AmyloidAmyotrophic Lateral SclerosisAutoantibodiesBrain IschemiaCase-Control Studiesgamma-SynucleinHumansAmyloidAutoantibodiesgamma-Synuclein

Identifiers

PMID28421431
OpenAlexW2605808620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.